DGFT changes Export Policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients from ‘Prohibited’ to ‘Restricted’ [Read Notification]
DGFT – Export policy of Injection Remdesivir – Remdesivir Active Pharmaceutical Ingredients – Taxscan
DGFT – Export policy of Injection Remdesivir – Remdesivir Active Pharmaceutical Ingredients – Taxscan
The Director-General of Foreign Trade (DGFT) notified the changes in the Export policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients from ‘Prohibited’ to ‘Restricted’.
Earlier the Centre prohibited exports of Remdesivir injection and Remdesivir Active Pharmaceutical Ingredients (API), anticipating an increase in demand for the drug used in the treatment of covid-19 patients amid a surge in coronavirus infections in the country.
Presently the export policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients is ‘Prohibited’. However, the policy has been revised to ‘Restricted’.
Further, export of Injection Remdesivir and Remdesivir API against Advance Authorizations issued under Chapter 4 of Foreign Trade Policy/Handbook of Procedures shall not require separate export authorization or permission.
“The export of Injection Remdesivir and Remdesivir API falling under above ITC HS Codes or any other HS Code has been restricted with immediate effect and export of the same against Advance Authorizations will not require separate export authorization or permission,” the DGFT notified.
To Read the full text of the Notification CLICK HERE
Support our journalism by subscribing to Taxscan AdFree. We welcome your comments at info@taxscan.in
